The coagulation cofactor Va (FVa) is a non-covalent heterodimer consisting of a heavy-chain (FVaH) and a light-chain (FVaL). Previously, the fibrinolytic effector plasmin (Pn) has been shown to inhibit FVa function. To understand this mechanism, the fragmentation profile of human FVa by Pn and non-covalent association of the derived fragments, were determined in the presence of Ca 2+ using aPL-coated microtiter wells and large (1 µm) aPL micelles as affinity matrices. Following Pn inactivation of aPLbound FVa, a total of 16 fragments were observed and their NH 2 -termini sequenced.
Summary
The coagulation cofactor Va (FVa) is a non-covalent heterodimer consisting of a heavy-chain (FVaH) and a light-chain (FVaL). Previously, the fibrinolytic effector plasmin (Pn) has been shown to inhibit FVa function. To understand this mechanism, the fragmentation profile of human FVa by Pn and non-covalent association of the derived fragments, were determined in the presence of Ca 2+ using aPL-coated microtiter wells and large (1 µm) aPL micelles as affinity matrices. Following Pn inactivation of aPLbound FVa, a total of 16 fragments were observed and their NH 2 -termini sequenced.
These had apparent molecular weights and starting residues as follows: 50(L1766) . Once formed, this macromolecular complex, termed prothrombinase, enhances the FXa-mediated activation of prothrombin to thrombin by five orders of magnitude (5), which is necessary for physiological clot formation.
Human FV is secreted into plasma as a single-chain glycoprotein (2196 a.a.)
composed of three homologous A-domains and two homologous C-domains, and a unique B-domain arranged in the order NH 2 -A1-A2-B-A3-C1-C2-CO 2 H (6, 7). FVa is a heterodimer comprised of an NH 2 -terminal-derived heavy chain (FVaH; A1/A2 domains; Mr = 104-kDa, amino acids 1-709), and a CO 2 H-terminal-derived light chain (FVaL;
A3/C1/C2 domains; Mr = 74/71-kDa; amino acids 1546-2196). FVaH and FVaL are noncovalently associated in the presence of a Ca 2+ (Kd = 6 X 10 -9 M) (8) and both chains are essential for full biological activity (9, 10) . Addition of a chelating agent such as EDTA disrupts this interaction (9-11) which can then be regained by recalcification (8, 10, 12, 13) resulting in the expression of a single Ca
2+
-binding site (Kd = 24 X 10 -6 M) (13 consisting of 75:25% mixture of PC/PS were prepared (25) and quantified as described (26) . Large vesicles (LV; 300-600 nm) were made by extrusion using a Liposofast Basic apparatus (Avestin Inc.). LV consisting of 1-4 mg of 75:25% PC/PS was suspended in 1 ml methanol in glass tubes and dried to a thin film under a steady stream of nitrogen at 4 °C. The phospholipid was resuspended in 0.5 -1 ml of 20 mM
Hepes, 300 mM sucrose, pH 7.4, vortexed for 1 min, and subjected to ten freeze-thaw cycles. The suspension was then extruded through two 1 µm filters (Avestin, Inc.) and collected. The vesicles were then mixed 1:1 with 20 mM Hepes, 150 mM NaCl, pH 7.4
(HBS/Ca 2+ ) and harvested by centrifugation at 13,000 x g at 22 °C for 5-10 min. The pellet was resuspended in HBS, and quantified using an assay for total phosphorous (27) .
ProteinsHuman FVa, FXa, prothrombin, plasminogen, Pn, monoclonal antibodies (mAb) specific for human FVaH (AHV-5146), and human FVaL (AHV-5112), and polyclonal sheep anti-human FV (PAHFV-S) were from Haematologic Technologies Inc. mAb specific for FVa A3 domain (anti-FVaA3) was produced by Dr.
R. Lemieux (Hema-Quebec) for which in-house recombinant FVaL produced using the Baculovirus system and purified by electroelution was used as antigen. PCRscreened R506Q homozygous plasma was a generous gift from Dr. M.C. Poon; U. Immobilon-P, Millipore) (29) . The PVDF membrane was blocked at 22 °C for 1 h in milk (5%), and cleavage products of FVa were detected by Western analysis using chemiluminescence (ECL).
FVa was also cleaved by Pn when bound to aPL-coated microtiter wells prepared as previously described (25) To determine whether the digestion profile was aPL-dependent, experiments were performed in the absence of aPL vesicles, but in the presence of Ca
. It was found that the rate of digestion of the light chain was accelerated in the presence of aPL, whereas the rate of digestion of the heavy chain was not altered (not shown).
Aprotinin completely inhibited the cleavage of FVa by Pn. No distinction in the size of fragments generated was observed when the digestion was performed in the absence or presence of aPL, although additional cleavages were observed when the interaction between FVaL and FVaH was inhibited by chelation (not shown).
Correlation Between Pn-Mediated FVa Fragments Remaining Bound to aPL
and Loss of Cofactor ActivityTo determine which fragments remained non-covalently associated with aPL in the presence of Ca
2+
, FVa was equilibrated with aPL-coated microtiter wells and fragments that remained bound to the plate after digestion with Pn were washed with buffer containing Ca
. Remaining fragments were analyzed by
Western blot using a FVaH-and two FVaL-specific mAb. These data showed that the fragments of 50-, 48-, 43-, 40-, and 30-kDa were light chain-derived ( Fig. 2A, 2B ).
Since the mAb in panel B recognizes the A3-domain, the completely different fragmentation pattern suggests the commercial mAb used in panel A has specificity for the C-terminal part of FVaL containing C1/C2. (Fig. 1) .
In order to correlate the appearance of degradation products with observed changes in FVa cofactor activity, fragments remaining bound to aPL were assayed for FVa function. Inactivation of FVa by Pn was rapid over the time course of the experiment (Fig. 2D) . Following 8 min incubation with Pn aPL-bound FVa was completely inactive. The rapid loss of cofactor activity coincided with appearance of the 30-kDa A3, 48-and minor 50-KDa C1/C2-derived fragments and with the 45-and minor 50-kDa heavy chain-derived fragments.
Cleavage of FV and FVa by Pn in a Fibrin
ClotHaving established the fragment composition of purified Pn-inactivated FVa, we determined whether these fragments were also generated under more physiological conditions. Thromboplastin was added to plasma to generate a fibrin clot, and the FV/FVa fragmentation pattern was examined following either Pn-or tPA-induced clot dissolution. Western blots (Fig.   3 ) showed that the FVaH-and FVaL-derived fragmentation pattern was identical to those in our purified system regardless of whether Pn or tPA was used to induce clot fibrinolysis. These data support the physiological relevance of the purified system. domain (starting at Leu94). The 30-kDa FVaH band was found to be two co-migrating species, which differed by 16 amino acids starting at residues Leu94 or Met110, and hence were referred to as 30(L94), and 30(M110). The 34-kDa fragment not detected by the mAbs, corresponded to the CO 2 H-terminal end of FVaH, and unexpectedly contained a conserved polymorphism at residue 352 (Leu to Thr) ( Fig 4B) . This is the first report to our knowledge of this substitution, which is consistent with FVa being purified from pooled plasma. Once generated, the 34-kDa fragment was quickly proteolysed into fragments of less than 7-kDa, of which several were sequenced. , resulting in association specifically with intact FVaL (Fig. 6C, inset . Of these only the 48-, and 43-kDa fragments remained bound in EDTA (Fig. 7A ). Sequence analyses (Fig. 7B) confirmed their identification. An unexpected observation was made concerned the co-migrating FVaH-derived 30 KDa fragments we identified in FVaH by Pn appears to occur by two cleavage pathways (Fig. 9B ) that ultimately lead to the loss of the A2 domain and the generation of a 30-kDa doublet. In the major cleavage pathway, the 30-kDa species is generated from a prominent 45-kDa NH 2 -terminal fragment. In the minor cleavage pathway, the 30-kDa fragment is generated from a 50-kDa intermediate NH 2 -terminal fragment which is produced from a 65-kDa fragment. The CO 2 H-terminal fragments from both pathways are quickly proteolysed to smaller fragments that migrate close to or at the dye-front (Mr < 7-kDa). In contrast, the 30-kDa fragment was observed to persist throughout the time of the experiment. To our knowledge, this study is the first to describe the Pn cleavage sites within human FVa, although in a preliminary report Kalafatis and Mann (33) presented NH 2 -
Identification of Pn Cleavage Sites in FVaTo
terminal amino acid sequence of Pn-cleaved fragments from bovine FVa (33) . The identity of some of these species differed from those presented here for human FVa, with cleavages at Arg348, Lys1656, and Arg1765 being in agreement.
To determine if the Pn-derived FVa fragments we observed in purified systems can occur in a physiological setting, we tested whether these fragments are generated The contribution of aPL to the assembly of prothrombinase components, and to the localization of thrombin production to the site of injury, has been well documented (37) (38) (39) (40) (41) (42) . Furthermore, it has been shown that FVaL confers all of the aPL-binding function of FVa (11, (43) (44) (45) (46) (47) and that this interaction is Ca 2+ -independent (11, 46, 48) .
Several studies suggest that the C2 domain contains the aPL-binding region of FVaL . These data suggest that a Ca 2+ sensitive site may be contained between Leu94 and Lys109.
Consistent with this hypothesis, X-ray structure and molecular modeling, using homologous protein templates based on the ceruloplasmin and factor VIII A-type domains, has suggested a putative Ca 2+ ion-binding site within the A1-A3 interface (57, 58) . Interestingly, of the five negatively charged residues (Glu96, Asp102, Glu108, Asp111, and Asp112) predicted to be involved in the Ca 2+ binding pocket in the A1 domain (57), three residues are located between amino acids Leu94 and Lys109, and the remainder are neighboring. While molecular modeling supports our finding that a Ca
2+
-sensitive region between Leu94 and Lys109 may exist, direct studies must be conducted to substantiate this likelihood.
To determine whether the observed Ca In addition to the inhibitory function Pn has on FVa coagulant activity (16, 17) , previous data from our laboratory has also suggested that Pn may convert FVa into a tPA accelerator (25) . To determine whether these combined regulatory roles could be applied to a prevalent thrombotic risk factor, the effect of the R506Q "Leiden" mutation The predicted minor cleavage pathway is depicted by dotted arrows. 
